Search results for "ENT"

Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

What will it take to build on the success of Lexraza, South Korea’s landmark lung cancer drug, and propel it into the next generation of...
Daewoong Pharmaceutical Enters Digital Therapeutics Market with Exclusive Deal for MCI Device 'Cogthera'

Daewoong Pharmaceutical Enters Digital Therapeutics Market with Exclusive Deal for MCI Device 'Cogthera'

Daewoong Pharmaceutical announced on the 22nd that it has signed an exclusive domestic sales and commercialization agreement with digital healthcare...
From 6 Opening-Day Patients to 3.13 Million Treated: Hana ENT Hospital Marks 30 Years

From 6 Opening-Day Patients to 3.13 Million Treated: Hana ENT Hospital Marks 30 Years

Hana ENT Hospital has published a 201-page white paper titled Patient-Centered to mark its 30th anniversary,...
South Korea Designates Top 3 Superbug Threats, Ranking Vancomycin-Resistant Enterococci Above WHO Priorities

South Korea Designates Top 3 Superbug Threats, Ranking Vancomycin-Resistant Enterococci Above WHO Priorities

An estimated 1. 14 million people worldwide died in 2021 from infections caused by antibiotic-resistant bacteria.
Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors

Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors

Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries

Daewoong Pharmaceutical’s botulinum toxin product Nabota has entered Kuwait, expanding its Middle East footprint to...
Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy

CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical...
117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years

117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years

A review of 25 major South Korean pharmaceutical and biotechnology companies revealed 117 recognized industrial...
The Probiotic Paradox: Why Your Daily Supplement Might Never Reach Your Gut

The Probiotic Paradox: Why Your Daily Supplement Might Never Reach Your Gut

These days, millions of people jumpstart their morning routines by reaching for a daily dose of probiotics.
The Daycare Dilemma: Why Hand, Foot, and Mouth Disease Spreads Long After Symptoms Fade

The Daycare Dilemma: Why Hand, Foot, and Mouth Disease Spreads Long After Symptoms Fade

“Mom, my mouth hurts so I can’t eat.” When a child suddenly puts down their spoon, a quick check inside the mouth often...